Epidemiological and Genomic Insights into SARS-CoV-2 in Lebanon: A Prospective Multicenter Analysis from 2020 to 2024 - Scorecard - MDSpire

Epidemiological and Genomic Insights into SARS-CoV-2 in Lebanon: A Prospective Multicenter Analysis from 2020 to 2024

  • By

  • Fatima Dakroub

  • Celina F. Boutros

  • Diego Teixeira

  • Habib Alkalamouni

  • Nagham Hamzah

  • Nancy Hourani

  • Amani Haddara

  • Samar Dalle

  • Dima Khreis

  • Elsy Tawil

  • Silma Baasiri

  • Zeinab El Zein

  • Mayse Naser

  • Rawan Korman

  • Maher Sraj

  • Yara Salameh

  • Sarah Merhi

  • Kawthar Faour

  • Nadim Tfaily

  • Stephanie Damaj

  • Mohammad Taleb

  • Soha Ghanem

  • Ghenwa Dakdouki

  • Rouba Shaker

  • Imad Chokr

  • David Breish

  • Maria Karam

  • Nada M. Melhem

  • Antoine Abou Fayad

  • Hassan Zaraket

  • Ewan M. Harrison

  • Ghassan M. Matar

  • Ghassan S. Dbaibo

  • January 28, 2026

  • 0 min

Share

Clinical Scorecard: Epidemiological and Genomic Insights into SARS-CoV-2 in Lebanon: A Prospective Multicenter Analysis from 2020 to 2024

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationHospitalized patients with confirmed COVID-19 in Lebanon
Care Setting

Key Highlights

  • SARS-CoV-2 variants have evolved, impacting clinical outcomes.
  • Omicron variant associated with milder disease and fewer hospitalizations.
  • Vaccination strategies must adapt to evolving viral strains.
  • Genomic surveillance is crucial for tracking SARS-CoV-2 variants.

Guideline-Based Recommendations

Diagnosis

  • Use ECDC-modified case definition for ILI in patients aged 5 and older.
  • Adopt WHO Extended SARI case definition for acute respiratory infections.

Management

  • Prioritize high-risk individuals for vaccination.
  • Monitor clinical characteristics and outcomes across different variants.

Monitoring & Follow-up

  • Conduct genomic surveillance to track SARS-CoV-2 variants.
  • Assess clinical implications of viral mutations.

Risks

  • Older age and comorbidities such as diabetes and cardiovascular disease increase severity and mortality.

Patient & Prescribing Data

Antiviral and antibiotic use documented; vaccination history recorded, including specific antiviral treatments and their effectiveness.

Clinical Best Practices

  • Collect comprehensive demographic and clinical data for all patients.
  • Ensure informed consent for participation in studies.
  • Provide ongoing training for healthcare providers on COVID-19 management.

References

Original Source(s)

Epidemiological and Genomic Insights into SARS-CoV-2 in Lebanon: A Prospective Multicenter Analysis from 2020 to 2024

  • by Fatima Dakroub, Celina F. Boutros, Diego Teixeira, Habib Alkalamouni, Nagham Hamzah, Nancy Hourani, Amani Haddara, Samar Dalle, Dima Khreis, Elsy Tawil, Silma Baasiri, Zeinab El Zein, Mayse Naser, Rawan Korman, Maher Sraj, Yara Salameh, Sarah Merhi, Kawthar Faour, Nadim Tfaily, Stephanie Damaj, Mohammad Taleb, Soha Ghanem, Ghenwa Dakdouki, Rouba Shaker, Imad Chokr, David Breish, Maria Karam, Nada M. Melhem, Antoine Abou Fayad, Hassan Zaraket, Ewan M. Harrison, Ghassan M. Matar, Ghassan S. Dbaibo

  • January 28, 2026

Related Content

Long-term epidemiological patterns of pediatric infectious diseases in an urban district of Shanghai, 2015–2023

Novel BPI3Vc-vectored chimeric BVDV antigens elicit broadly neutralizing antibodies in cattle

The latest developments on Ebola, hepatitis B, long Covid